DERMTECH INC (DMTK) Fundamental Analysis & Valuation
NASDAQ:DMTK • US24984K1051
Current stock price
0.094 USD
-0.01 (-11.32%)
At close:
0.095 USD
+0 (+1.06%)
After Hours:
This DMTK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. DMTK Profitability Analysis
1.1 Basic Checks
- DMTK had negative earnings in the past year.
- In the past year DMTK has reported a negative cash flow from operations.
- DMTK had negative earnings in 4 of the past 5 years.
- DMTK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- DMTK has a Return On Assets of -87.04%. This is in the lower half of the industry: DMTK underperforms 73.69% of its industry peers.
- DMTK's Return On Equity of -224.09% is on the low side compared to the rest of the industry. DMTK is outperformed by 71.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.04% | ||
| ROE | -224.09% | ||
| ROIC | N/A |
ROA(3y)-57.34%
ROA(5y)-43.66%
ROE(3y)-99.56%
ROE(5y)-68.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Gross Margin value of 8.51%, DMTK is doing good in the industry, outperforming 74.22% of the companies in the same industry.
- The Profit Margin and Operating Margin are not available for DMTK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 8.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. DMTK Health Analysis
2.1 Basic Checks
- DMTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, DMTK has more shares outstanding
- The debt/assets ratio for DMTK has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -8.44, we must say that DMTK is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -8.44, DMTK is doing worse than 73.69% of the companies in the same industry.
- A Debt/Equity ratio of 0.00 indicates that DMTK is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.00, DMTK perfoms like the industry average, outperforming 49.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.44 |
ROIC/WACCN/A
WACC10.37%
2.3 Liquidity
- A Current Ratio of 3.53 indicates that DMTK has no problem at all paying its short term obligations.
- DMTK has a worse Current ratio (3.53) than 61.85% of its industry peers.
- DMTK has a Quick Ratio of 3.46. This indicates that DMTK is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of DMTK (3.46) is worse than 61.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.53 | ||
| Quick Ratio | 3.46 |
3. DMTK Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 30.77% over the past year.
- The Revenue has grown by 9.80% in the past year. This is quite good.
- DMTK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.45% yearly.
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.14%
Revenue 1Y (TTM)9.8%
Revenue growth 3Y37.45%
Revenue growth 5YN/A
Sales Q2Q%10.58%
3.2 Future
- Based on estimates for the next years, DMTK will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.08% on average per year.
- DMTK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.40% yearly.
EPS Next Y35.19%
EPS Next 2Y15.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.8%
Revenue Next 2Y6.4%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. DMTK Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for DMTK. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DMTK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as DMTK's earnings are expected to grow with 15.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.08%
EPS Next 3YN/A
5. DMTK Dividend Analysis
5.1 Amount
- No dividends for DMTK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DMTK Fundamentals: All Metrics, Ratios and Statistics
0.094
-0.01 (-11.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2024-05-14/amc
Earnings (Next)08-01 2024-08-01/amc
Inst Owners1.25%
Inst Owner Change0%
Ins Owners14.8%
Ins Owner Change0%
Market Cap3.29M
Revenue(TTM)15.67M
Net Income(TTM)-89.62M
Analysts43.33
Price Target1.53 (1527.66%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.37%
Min EPS beat(2)2.83%
Max EPS beat(2)7.91%
EPS beat(4)4
Avg EPS beat(4)9.33%
Min EPS beat(4)0.28%
Max EPS beat(4)26.31%
EPS beat(8)7
Avg EPS beat(8)4.76%
EPS beat(12)7
Avg EPS beat(12)-0.55%
EPS beat(16)9
Avg EPS beat(16)-3.77%
Revenue beat(2)0
Avg Revenue beat(2)-5.25%
Min Revenue beat(2)-5.62%
Max Revenue beat(2)-4.87%
Revenue beat(4)1
Avg Revenue beat(4)-1.59%
Min Revenue beat(4)-5.62%
Max Revenue beat(4)5.68%
Revenue beat(8)2
Avg Revenue beat(8)-4.65%
Revenue beat(12)3
Avg Revenue beat(12)-4.35%
Revenue beat(16)7
Avg Revenue beat(16)3.66%
PT rev (1m)-26.59%
PT rev (3m)-46.43%
EPS NQ rev (1m)-10.64%
EPS NQ rev (3m)-0.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0.25%
Revenue NQ rev (1m)-7.64%
Revenue NQ rev (3m)-8.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.08 | ||
| P/tB | 0.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.7
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-2.07
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0.45
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.04% | ||
| ROE | -224.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 8.51% | ||
| FCFM | N/A |
ROA(3y)-57.34%
ROA(5y)-43.66%
ROE(3y)-99.56%
ROE(5y)-68.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.7% | ||
| Cap/Sales | 0.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.53 | ||
| Quick Ratio | 3.46 | ||
| Altman-Z | -8.44 |
F-Score3
WACC10.37%
ROIC/WACCN/A
Cap/Depr(3y)174.84%
Cap/Depr(5y)226.26%
Cap/Sales(3y)17.22%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.14%
EPS Next Y35.19%
EPS Next 2Y15.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.8%
Revenue growth 3Y37.45%
Revenue growth 5YN/A
Sales Q2Q%10.58%
Revenue Next Year16.8%
Revenue Next 2Y6.4%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.62%
EBIT Next 3Y9.65%
EBIT Next 5YN/A
FCF growth 1Y9.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.43%
OCF growth 3YN/A
OCF growth 5YN/A
DERMTECH INC / DMTK Fundamental Analysis FAQ
What is the ChartMill fundamental rating of DERMTECH INC (DMTK) stock?
ChartMill assigns a fundamental rating of 2 / 10 to DMTK.
Can you provide the valuation status for DERMTECH INC?
ChartMill assigns a valuation rating of 0 / 10 to DERMTECH INC (DMTK). This can be considered as Overvalued.
How profitable is DERMTECH INC (DMTK) stock?
DERMTECH INC (DMTK) has a profitability rating of 1 / 10.
What is the financial health of DERMTECH INC (DMTK) stock?
The financial health rating of DERMTECH INC (DMTK) is 3 / 10.